Similar articles

• The use of levofloxacin in the treatment of respiratory tract infection.

  Shah PM. Shah PM. J Chemother. 2000 Oct;12 Suppl 4:27-31. doi: 10.1080/1120009x.2000.11782310. J Chemother. 2000. PMID: 11131957 Review.
• [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].

  Budanov SV, Vasil'ev AN, Smirnova LB. Budanov SV, et al. Antibiot Khimioter. 2001;46(7):38-46. Antibiot Khimioter. 2001. PMID: 11697244 Review. Russian. No abstract available.
• [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].

  Scheen AJ. Scheen AJ. Rev Med Liege. 2000 Nov;55(11):1015-7. Rev Med Liege. 2000. PMID: 11195704 French.
• Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.

  Kawai T. Kawai T. Drugs. 1995;49 Suppl 2:416-7. doi: 10.2165/00003495-199500492-00119. Drugs. 1995. PMID: 8549383 Clinical Trial. No abstract available.
• Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.

  Shishido H, Furukawa K, Nagai H, Kawakami K, Kono H. Shishido H, et al. Drugs. 1995;49 Suppl 2:433-5. doi: 10.2165/00003495-199500492-00126. Drugs. 1995. PMID: 8549391 Clinical Trial. No abstract available.